Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Treatment of oral cancer using magnetized paclitaxel.

Nakakaji R, Umemura M, Mitsudo K, Kim JH, Hoshino Y, Sato I, Masuda T, Yamamoto M, Kioi M, Koizumi T, Fujita T, Yokoyama U, Iida M, Sato M, Sato H, Murofushi S, Shibata S, Aoki I, Eguchi H, Tohnai I, Ishikawa Y.

Oncotarget. 2018 Feb 26;9(21):15591-15605. doi: 10.18632/oncotarget.24570. eCollection 2018 Mar 20.

2.

Chemoradiotherapy using retrograde superselective intra-arterial infusion for tongue cancer: Analysis of therapeutic results in 118 cases.

Mitsudo K, Hayashi Y, Minamiyama S, Ohashi N, Iida M, Iwai T, Oguri S, Koizumi T, Kioi M, Hirota M, Koike I, Hata M, Tohnai I.

Oral Oncol. 2018 Apr;79:71-77. doi: 10.1016/j.oraloncology.2018.02.002. Epub 2018 Mar 9.

3.

Multicenter retrospective study of cetuximab plus platinum-based chemotherapy for recurrent or metastatic oral squamous cell carcinoma.

Yanamoto S, Umeda M, Kioi M, Kirita T, Yamashita T, Hiratsuka H, Yokoo S, Tanzawa H, Uzawa N, Shibahara T, Ota Y, Kurita H, Okura M, Hamakawa H, Kusukawa J, Tohnai I.

Cancer Chemother Pharmacol. 2018 Mar;81(3):549-554. doi: 10.1007/s00280-018-3531-x. Epub 2018 Jan 30.

PMID:
29383483
4.

Clinical outcomes of retrograde intra-arterial chemotherapy concurrent with radiotherapy for elderly oral squamous cell carcinoma patients aged over 80 years old.

Hayashi Y, Mitsudo K, Sakuma K, Iida M, Iwai T, Nakashima H, Okamoto Y, Koizumi T, Oguri S, Hirota M, Kioi M, Koike I, Hata M, Tohnai I.

Radiat Oncol. 2017 Jul 3;12(1):112. doi: 10.1186/s13014-017-0847-3.

5.

Retrograde superselective intra-arterial chemotherapy and daily concurrent radiotherapy for T2-4N0 tongue cancer: control of occult neck metastasis.

Minamiyama S, Mitsudo K, Hayashi Y, Iida M, Iwai T, Nakashima H, Oguri S, Ozawa T, Koizumi T, Hirota M, Kioi M, Tohnai I.

Oral Surg Oral Med Oral Pathol Oral Radiol. 2017 Jul;124(1):16-23. doi: 10.1016/j.oooo.2017.02.004. Epub 2017 Feb 21.

PMID:
28434836
6.

Triphala, a formulation of traditional Ayurvedic medicine, shows protective effect against X-radiation in HeLa cells.

Takauji Y, Miki K, Mita J, Hossain MN, Yamauchi M, Kioi M, Ayusawa D, Fujii M.

J Biosci. 2016 Dec;41(4):569-575.

7.

Intraosseous inflammatory myofibroblastic tumor of the mandible with a novel ATIC-ALK fusion mutation: a case report.

Tateishi Y, Okudela K, Kawai S, Suzuki T, Umeda S, Matsumura M, Kioi M, Ohashi K.

Diagn Pathol. 2016 Nov 15;11(1):132.

8.

M2-polarized macrophages contribute to neovasculogenesis, leading to relapse of oral cancer following radiation.

Okubo M, Kioi M, Nakashima H, Sugiura K, Mitsudo K, Aoki I, Taniguchi H, Tohnai I.

Sci Rep. 2016 Jun 8;6:27548. doi: 10.1038/srep27548.

9.

Simultaneous hyperthermia-chemotherapy with controlled drug delivery using single-drug nanoparticles.

Sato I, Umemura M, Mitsudo K, Fukumura H, Kim JH, Hoshino Y, Nakashima H, Kioi M, Nakakaji R, Sato M, Fujita T, Yokoyama U, Okumura S, Oshiro H, Eguchi H, Tohnai I, Ishikawa Y.

Sci Rep. 2016 Apr 22;6:24629. doi: 10.1038/srep24629.

10.

Prognostic value of 2-[(18) F]fluoro-2-deoxy-D-glucose positron emission tomography for patients with oral squamous cell carcinoma treated with retrograde superselective intra-arterial chemotherapy and daily concurrent radiotherapy.

Shimizu M, Mitsudo K, Koike I, Taguri M, Iwai T, Koizumi T, Oguri S, Kioi M, Hirota M, Inoue T, Tohnai I.

Oral Surg Oral Med Oral Pathol Oral Radiol. 2016 Mar;121(3):239-47. doi: 10.1016/j.oooo.2015.10.018. Epub 2015 Oct 24.

PMID:
26768076
11.

Increase of peripheral blood CD57+ T-cells in patients with oral squamous cell carcinoma.

Iida M, Takayama E, Naganawa K, Mitsudo K, Adachi M, Baba J, Fujimoto-Muto M, Motohashi M, Mizuno-Kamiya M, Kawaki H, Kioi M, Ichinose M, Sumitomo S, Muramatsu Y, Shikimori M, Tohnai I, Kondoh N.

Anticancer Res. 2014 Oct;34(10):5729-34.

PMID:
25275081
12.

Retrograde superselective intra-arterial chemotherapy and daily concurrent radiotherapy for stage III and IV oral cancer: analysis of therapeutic results in 112 cases.

Mitsudo K, Koizumi T, Iida M, Iwai T, Nakashima H, Oguri S, Kioi M, Hirota M, Koike I, Hata M, Tohnai I.

Radiother Oncol. 2014 May;111(2):306-10. doi: 10.1016/j.radonc.2014.03.005. Epub 2014 Apr 17.

PMID:
24746571
13.

Hyperthermia generated with ferucarbotran (Resovist®) in an alternating magnetic field enhances cisplatin-induced apoptosis of cultured human oral cancer cells.

Sato I, Umemura M, Mitsudo K, Kioi M, Nakashima H, Iwai T, Feng X, Oda K, Miyajima A, Makino A, Iwai M, Fujita T, Yokoyama U, Okumura S, Sato M, Eguchi H, Tohnai I, Ishikawa Y.

J Physiol Sci. 2014 May;64(3):177-83. doi: 10.1007/s12576-014-0309-8. Epub 2014 Mar 12.

PMID:
24619404
14.

Inhibition of CXCR7 extends survival following irradiation of brain tumours in mice and rats.

Walters MJ, Ebsworth K, Berahovich RD, Penfold ME, Liu SC, Al Omran R, Kioi M, Chernikova SB, Tseng D, Mulkearns-Hubert EE, Sinyuk M, Ransohoff RM, Lathia JD, Karamchandani J, Kohrt HE, Zhang P, Powers JP, Jaen JC, Schall TJ, Merchant M, Recht L, Brown JM.

Br J Cancer. 2014 Mar 4;110(5):1179-88. doi: 10.1038/bjc.2013.830. Epub 2014 Jan 14.

15.

Radiation therapy with concurrent retrograde superselective intra-arterial chemotherapy for gingival carcinoma.

Mukai Y, Hata M, Mitsudo K, Koike I, Koizumi T, Oguri S, Kioi M, Omura M, Tohnai I, Inoue T.

Strahlenther Onkol. 2014 Feb;190(2):181-5. doi: 10.1007/s00066-013-0468-1. Epub 2013 Nov 23.

PMID:
24264464
16.

SIRT7 links H3K18 deacetylation to maintenance of oncogenic transformation.

Barber MF, Michishita-Kioi E, Xi Y, Tasselli L, Kioi M, Moqtaderi Z, Tennen RI, Paredes S, Young NL, Chen K, Struhl K, Garcia BA, Gozani O, Li W, Chua KF.

Nature. 2012 Jul 5;487(7405):114-8. doi: 10.1038/nature11043.

17.

Thermochemoradiation therapy using superselective intra-arterial infusion via superficial temporal and occipital arteries for oral cancer with N3 cervical lymph node metastases.

Mitsudo K, Koizumi T, Iida M, Iwai T, Oguri S, Yamamoto N, Itoh Y, Kioi M, Hirota M, Tohnai I.

Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):e639-45. doi: 10.1016/j.ijrobp.2012.02.057. Epub 2012 Apr 28.

PMID:
22543212
18.

NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming.

Kuo AJ, Cheung P, Chen K, Zee BM, Kioi M, Lauring J, Xi Y, Park BH, Shi X, Garcia BA, Li W, Gozani O.

Mol Cell. 2011 Nov 18;44(4):609-20. doi: 10.1016/j.molcel.2011.08.042.

19.

Etodolac improves 5-FU sensitivity of head and neck cancer cells through inhibition of thymidylate synthase.

Murata S, Adachi M, Kioi M, Torigoe S, Ijichi K, Hasegawa Y, Ogawa T, Bhayani MK, Lai SY, Mitsudo K, Tohnai I.

Anticancer Res. 2011 Sep;31(9):2893-8.

PMID:
21868535
20.

Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice.

Kioi M, Vogel H, Schultz G, Hoffman RM, Harsh GR, Brown JM.

J Clin Invest. 2010 Mar;120(3):694-705. doi: 10.1172/JCI40283. Epub 2010 Feb 22.

21.

Identification of potential therapeutic targets in human head & neck squamous cell carcinoma.

Han J, Kioi M, Chu WS, Kasperbauer JL, Strome SE, Puri RK.

Head Neck Oncol. 2009 Jul 14;1:27. doi: 10.1186/1758-3284-1-27.

22.

IL-13 cytotoxin has potent antitumor activity and synergizes with paclitaxel in a mouse model of oral squamous cell carcinoma.

Kioi M, Shimamura T, Nakashima H, Hirota M, Tohnai I, Husain SR, Puri RK.

Int J Cancer. 2009 Mar 15;124(6):1440-8. doi: 10.1002/ijc.24067.

23.

Optimized clostridium-directed enzyme prodrug therapy improves the antitumor activity of the novel DNA cross-linking agent PR-104.

Liu SC, Ahn GO, Kioi M, Dorie MJ, Patterson AV, Brown JM.

Cancer Res. 2008 Oct 1;68(19):7995-8003. doi: 10.1158/0008-5472.CAN-08-1698.

24.

Novel role of IL-13 in fibrosis induced by nonalcoholic steatohepatitis and its amelioration by IL-13R-directed cytotoxin in a rat model.

Shimamura T, Fujisawa T, Husain SR, Kioi M, Nakajima A, Puri RK.

J Immunol. 2008 Oct 1;181(7):4656-65.

25.

Anaplasma phagocytophilum-induced gene expression in both human neutrophils and HL-60 cells.

Lee HC, Kioi M, Han J, Puri RK, Goodman JL.

Genomics. 2008 Sep;92(3):144-51. doi: 10.1016/j.ygeno.2008.05.005. Epub 2008 Jul 7.

26.

Targeting IL-13Ralpha2-positive cancer with a novel recombinant immunotoxin composed of a single-chain antibody and mutated Pseudomonas exotoxin.

Kioi M, Seetharam S, Puri RK.

Mol Cancer Ther. 2008 Jun;7(6):1579-87. doi: 10.1158/1535-7163.MCT-07-2131.

27.

SIRT6 is a histone H3 lysine 9 deacetylase that modulates telomeric chromatin.

Michishita E, McCord RA, Berber E, Kioi M, Padilla-Nash H, Damian M, Cheung P, Kusumoto R, Kawahara TL, Barrett JC, Chang HY, Bohr VA, Ried T, Gozani O, Chua KF.

Nature. 2008 Mar 27;452(7186):492-6. doi: 10.1038/nature06736. Epub 2008 Mar 12.

28.

Interleukin-4 cytotoxin therapy synergizes with gemcitabine in a mouse model of pancreatic ductal adenocarcinoma.

Shimamura T, Royal RE, Kioi M, Nakajima A, Husain SR, Puri RK.

Cancer Res. 2007 Oct 15;67(20):9903-12.

29.

N-linked glycosylation of IL-13R alpha2 is essential for optimal IL-13 inhibitory activity.

Kioi M, Seetharam S, Puri RK.

FASEB J. 2006 Nov;20(13):2378-80. Epub 2006 Oct 3.

PMID:
17023392
30.

Interleukin-13 receptor alpha2 chain: a potential biomarker and molecular target for ovarian cancer therapy.

Kioi M, Kawakami M, Shimamura T, Husain SR, Puri RK.

Cancer. 2006 Sep 15;107(6):1407-18.

31.

Intratumoral therapy with IL13-PE38 results in effective CTL-mediated suppression of IL-13Ralpha2-expressing contralateral tumors.

Kawakami K, Terabe M, Kioi M, Berzofsky JA, Puri RK.

Clin Cancer Res. 2006 Aug 1;12(15):4678-86.

32.

Convection-enhanced delivery of interleukin-13 receptor-directed cytotoxin for malignant glioma therapy.

Kioi M, Husain SR, Croteau D, Kunwar S, Puri RK.

Technol Cancer Res Treat. 2006 Jun;5(3):239-50. Review.

PMID:
16700620
33.

Binding of active matrilysin to cell surface cholesterol sulfate is essential for its membrane-associated proteolytic action and induction of homotypic cell adhesion.

Yamamoto K, Higashi S, Kioi M, Tsunezumi J, Honke K, Miyazaki K.

J Biol Chem. 2006 Apr 7;281(14):9170-80. Epub 2006 Feb 13.

34.

Expression and targeting of interleukin-4 receptor for primary and advanced ovarian cancer therapy.

Kioi M, Takahashi S, Kawakami M, Kawakami K, Kreitman RJ, Puri RK.

Cancer Res. 2005 Sep 15;65(18):8388-96.

35.
36.

Hodgkin lymphoma therapy with interleukin-4 receptor-directed cytotoxin in an infiltrating animal model.

Kawakami M, Kawakami K, Kioi M, Leland P, Puri RK.

Blood. 2005 May 1;105(9):3707-13. Epub 2004 Dec 30.

37.

Distribution kinetics of targeted cytotoxin in glioma by bolus or convection-enhanced delivery in a murine model.

Kawakami K, Kawakami M, Kioi M, Husain SR, Puri RK.

J Neurosurg. 2004 Dec;101(6):1004-11.

PMID:
15597761
38.
39.

Mechanism of action of interleukin-13 antagonist (IL-13E13K) in cells expressing various types of IL-4R.

Kioi M, Kawakami K, Puri RK.

Cell Immunol. 2004 May;229(1):41-51.

PMID:
15331327
40.

Matrilysin (MMP-7) induces homotypic adhesion of human colon cancer cells and enhances their metastatic potential in nude mouse model.

Kioi M, Yamamoto K, Higashi S, Koshikawa N, Fujita K, Miyazaki K.

Oncogene. 2003 Nov 27;22(54):8662-70.

PMID:
14647460

Supplemental Content

Support Center